2014 Fiscal Year Final Research Report
An analgesic effect of NAAG peptidase inhibitor injected into locus coeruleus
| Project/Area Number |
25860426
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pain science
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Keywords | 侵害刺激 / グルタミン酸代謝型受容体 / 青斑核 / 炎症性痛 |
|---|
| Outline of Final Research Achievements |
N-acetyl-aspartyl-glutamate (NAAG) is one of the most abundant neurotransmitter in the mammalian central nervous system. It has been reported that NAAG acts as a mGluR3 agonist and that NAAG peptidase inhibitors, such as 2-PMPA and ZJ43, have an analgesic property in inflammatory pain, neuropathic pain and cancer pain models when they are administered systemically, intrathecally, intracerebroventriculary or locally. In the present study, I investigated the effect of NAAG peptidase inhibitor injected into the locus coeruleus (LC) in the brain. NAAG peptidase inhibitor injected into LC produced an analgesic effect in the rat formalin test and this effect was antagonized by LY341495, an antagonist of mGluR3. I also found that NAAG peptidase inhibitor injected into LC induced noradrenalin released in the spinal cord. These data suggested that NAAG peptidase inhibitor have a potential to be a clinical analgesic drug.
|
| Free Research Field |
麻酔科
|
